Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.6K
Regulated Protein Degradation02:58

Regulated Protein Degradation

7.1K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.1K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

8.2K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.4K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intracellular Delivery of Peptides and Proteins with an Engineered Membrane Translocation Domain.

ACS chemical biology·2026
Same author

Discovery of a Minimally Charged Cell-Penetrating Peptide.

Biochemistry·2026
Same author

Intracellular Delivery of Peptides and Proteins with an Engineered Membrane Translocation Domain.

bioRxiv : the preprint server for biology·2026
Same author

Endosomal Escape of Lipid Nanoparticles: A Perspective on the Literature Data.

ACS nano·2025
Same author

Bismuth-Cyclized Cell-Penetrating Peptides.

Molecular pharmaceutics·2024
Same author

Cell-Penetrating Peptides Translocate across the Plasma Membrane by Inducing Vesicle Budding and Collapse.

Journal of the American Chemical Society·2024
Same journal

Discovery of Effective Dual PROTAC Degraders with Synergistic Antitumor Activity for Overcoming Tamoxifen-Resistant Breast Cancer.

Journal of medicinal chemistry·2026
Same journal

In Silico ADMET: From Current Practices to Novel Profilers.

Journal of medicinal chemistry·2026
Same journal

A Zirconium Aza-BODIPY Derivative as a Near-Infrared Fluorescent/Photoacoustic Imaging Bimodal Probe.

Journal of medicinal chemistry·2026
Same journal

Landscaping the Nitazene Scaffold to Identify Novel Mu-Opioid Receptor Modulators: From Molecular Design and Chemical Synthesis to Pharmacological Profiling.

Journal of medicinal chemistry·2026
Same journal

Development of Indole-3-yl-methylene-thiobarbital Derivatives as Inhibitors of HDAC8 Enzyme Activity.

Journal of medicinal chemistry·2026
Same journal

Discovery of a Potent NAMPT-Targeting PROTAC for the Suppression of Triple-Negative Breast Cancer via Macrophage Reprogramming.

Journal of medicinal chemistry·2026
See all related articles

Related Experiment Video

Updated: May 27, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.4K

Turning Off STAT6 with a Targeted Degrader.

Dehua Pei1

  • 1Department of Chemistry and Biochemistry, The Ohio State University, 484 West 12th Ave., Columbus, Ohio 43210, United States.

Journal of Medicinal Chemistry
|February 20, 2025
PubMed
Summary
This summary is machine-generated.

Researchers developed a potent and selective STAT6 degrader, overcoming decades of challenges in targeting signal transducer and activator of transcription 6 (STAT6) for disease treatment with minimal side effects.

More Related Videos

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

14.9K
Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
08:42

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model

Published on: July 3, 2020

4.3K

Related Experiment Videos

Last Updated: May 27, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.4K
Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

14.9K
Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
08:42

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model

Published on: July 3, 2020

4.3K

Area of Science:

  • Molecular biology
  • Drug discovery
  • Medicinal chemistry

Background:

  • Signal transducer and activator of transcription 6 (STAT6) is a key protein implicated in various human diseases.
  • STAT6 has been a challenging target for drug development for many years.
  • Developing effective therapeutics for STAT6-related conditions remains a significant unmet medical need.

Purpose of the Study:

  • To report the discovery of a novel STAT6 degrader.
  • To characterize the potency and selectivity of the identified STAT6 degrader.
  • To highlight the potential of this degrader for therapeutic applications.

Main Methods:

  • High-throughput screening and medicinal chemistry optimization were employed.
  • Biochemical and cellular assays were used to assess potency and selectivity.
  • Off-target activity profiling was conducted to ensure safety.

Main Results:

  • A highly potent and selective STAT6 degrader was successfully identified.
  • The degrader demonstrated minimal activity against off-target proteins.
  • The compound's properties suggest a promising therapeutic profile.

Conclusions:

  • The discovery represents a breakthrough in targeting STAT6.
  • This potent and selective STAT6 degrader offers a new therapeutic avenue.
  • Further development of this compound could lead to novel treatments for various diseases.